- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.20 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 2 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 7 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.2: 8 residues within 4Å:- Chain A: N.256, T.258, N.259
- Chain C: Q.1, H.3, Y.25, G.26, N.28
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:Q.1, C:Q.1
NAG-NAG-BMA.5: 11 residues within 4Å:- Chain A: D.191, P.192, L.241, N.242, N.355, C.356, R.357, C.417, L.418, S.419
- Ligands: NAG.24
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:L.418
- Hydrogen bonds: A:L.418
NAG-NAG-BMA.6: 13 residues within 4Å:- Chain B: N.126
- Chain C: W.108, S.109
- Chain D: N.32, Y.50, R.51, G.52, A.53, A.54, L.55, L.56, G.57, A.67
2 PLIP interactions:2 interactions with chain D- Hydrogen bonds: D:A.53, D:L.55
NAG-NAG-BMA.10: 10 residues within 4Å:- Chain E: D.191, L.241, N.242, N.355, C.356, R.357, C.417, L.418, S.419
- Ligands: NAG.38
2 PLIP interactions:2 interactions with chain E- Hydrophobic interactions: E:L.418
- Hydrogen bonds: E:L.418
NAG-NAG-BMA.11: 11 residues within 4Å:- Chain F: N.126
- Chain G: W.108, S.109
- Chain H: N.32, Y.50, R.51, G.52, A.53, A.54, L.55, G.57
2 PLIP interactions:2 interactions with chain H- Hydrogen bonds: H:A.53, H:L.55
NAG-NAG-BMA.18: 11 residues within 4Å:- Chain I: D.191, P.192, L.241, N.242, N.355, C.356, R.357, C.417, L.418, S.419
- Ligands: NAG.54
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:L.418
NAG-NAG-BMA.19: 12 residues within 4Å:- Chain J: N.126
- Chain K: S.109
- Chain L: N.32, Y.50, R.51, G.52, A.53, A.54, L.55, L.56, G.57, A.67
1 PLIP interactions:1 interactions with chain L- Hydrogen bonds: L:L.55
- 3 x NAG- NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-NAG-NAG.3: 16 residues within 4Å:- Chain A: T.277, Y.309, N.311, T.385, T.387, K.416
- Chain M: R.103, I.104, Y.105, G.106, V.107, V.108
- Chain N: N.45, D.62, I.63
- Ligands: NAG.22
3 PLIP interactions:1 interactions with chain M, 2 interactions with chain N- Hydrogen bonds: M:R.103, N:N.45, N:D.62
NAG-NAG-NAG-NAG.9: 13 residues within 4Å:- Chain E: T.277, Y.309, N.311, T.385, T.387, K.416
- Chain O: R.103, I.104, G.106, V.107, V.108
- Chain P: D.62
- Ligands: NAG.35
1 PLIP interactions:1 interactions with chain O- Hydrogen bonds: O:R.103
NAG-NAG-NAG-NAG.15: 17 residues within 4Å:- Chain I: T.277, R.306, Y.309, N.311, T.385, T.387, K.416
- Chain Q: R.103, I.104, Y.105, G.106, V.107, V.108
- Chain R: N.45, Q.47, P.61, D.62
5 PLIP interactions:2 interactions with chain Q, 3 interactions with chain R- Hydrogen bonds: Q:R.103, Q:R.103, R:N.45, R:Q.47, R:Q.47
- 4 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.4: 3 residues within 4Å:- Chain A: M.351, N.364, T.366
No protein-ligand interaction detected (PLIP)NAG-NAG.14: 6 residues within 4Å:- Chain I: E.248, G.249, I.250, N.269, E.270, R.323
No protein-ligand interaction detected (PLIP)NAG-NAG.16: 4 residues within 4Å:- Chain I: V.155, R.172, N.177, T.178
No protein-ligand interaction detected (PLIP)NAG-NAG.17: 4 residues within 4Å:- Chain I: N.101, Y.146, F.168, E.170
1 PLIP interactions:1 interactions with chain I- Hydrophobic interactions: I:F.168
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 42 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.20: 1 residues within 4Å:- Chain A: N.133
Ligand excluded by PLIPNAG.21: 1 residues within 4Å:- Chain A: N.221
Ligand excluded by PLIPNAG.22: 8 residues within 4Å:- Chain A: K.273, N.275, N.311, I.312, S.313, T.385, L.418
- Ligands: NAG-NAG-NAG-NAG.3
Ligand excluded by PLIPNAG.23: 3 residues within 4Å:- Chain A: N.281, I.302
- Chain N: F.65
Ligand excluded by PLIPNAG.24: 4 residues within 4Å:- Chain A: N.242, S.271, N.420
- Ligands: NAG-NAG-BMA.5
Ligand excluded by PLIPNAG.25: 5 residues within 4Å:- Chain A: N.129, Y.146, L.148, G.299, D.300
Ligand excluded by PLIPNAG.26: 4 residues within 4Å:- Chain A: E.248, I.250, N.269, R.323
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain A: T.366, N.370
Ligand excluded by PLIPNAG.28: 3 residues within 4Å:- Chain A: V.155, R.172, N.177
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain A: N.101, F.168, E.170
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain B: N.105
- Chain D: Q.27
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain B: N.113, N.114
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain C: K.87, N.88
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain E: N.133
- Chain I: D.140
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain E: H.56, N.209, N.221
Ligand excluded by PLIPNAG.35: 7 residues within 4Å:- Chain E: N.275, N.311, I.312, S.313, T.385, L.418
- Ligands: NAG-NAG-NAG-NAG.9
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain E: N.281, N.282, I.302
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain E: N.334
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain E: S.271, N.420
- Ligands: NAG-NAG-BMA.10
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain E: N.129, Y.146, L.148, D.300
Ligand excluded by PLIPNAG.40: 6 residues within 4Å:- Chain E: E.248, G.249, I.250, N.269, E.270, R.323
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain E: M.351, N.364, T.366
Ligand excluded by PLIPNAG.42: 1 residues within 4Å:- Chain E: N.370
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain E: V.155, R.172, N.177
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain E: N.101, F.168
Ligand excluded by PLIPNAG.45: 5 residues within 4Å:- Chain F: P.98, N.100, S.102, W.103, I.134
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain F: S.101, N.105
- Chain H: S.28
Ligand excluded by PLIPNAG.47: 1 residues within 4Å:- Chain F: N.114
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain G: S.17, N.88
Ligand excluded by PLIPNAG.49: 1 residues within 4Å:- Chain I: N.133
Ligand excluded by PLIPNAG.50: 2 residues within 4Å:- Chain I: N.209, N.221
Ligand excluded by PLIPNAG.51: 6 residues within 4Å:- Chain I: N.275, N.311, I.312, S.313, T.385, L.418
Ligand excluded by PLIPNAG.52: 2 residues within 4Å:- Chain I: N.281, V.414
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain I: K.329, N.334
Ligand excluded by PLIPNAG.54: 4 residues within 4Å:- Chain I: L.245, S.271, N.420
- Ligands: NAG-NAG-BMA.18
Ligand excluded by PLIPNAG.55: 4 residues within 4Å:- Chain I: N.129, Y.146, L.148, D.300
Ligand excluded by PLIPNAG.56: 4 residues within 4Å:- Chain I: T.350, M.351, N.364, T.366
Ligand excluded by PLIPNAG.57: 1 residues within 4Å:- Chain I: N.370
Ligand excluded by PLIPNAG.58: 4 residues within 4Å:- Chain J: P.98, N.100, W.103, I.134
Ligand excluded by PLIPNAG.59: 2 residues within 4Å:- Chain J: N.105
- Chain L: Q.27
Ligand excluded by PLIPNAG.60: 2 residues within 4Å:- Chain J: N.113, N.114
Ligand excluded by PLIPNAG.61: 3 residues within 4Å:- Chain K: G.15, R.66, N.88
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Prevost, J. et al., Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir. Nat Commun (2023)
- Release Date
- 2023-07-19
- Peptides
- CRF-1_AE T/F100 Env gp120: AEI
CRF-1_AE T/F100 HIV-1 gp41: BFJ
Heavy chain of 8ANC195: CGK
Light chain of 8ANC195: DHL
Heavy chain of 10-1074: MOQ
Light chain of 10-1074: NPR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
EI
IB
BF
FJ
JC
CG
GK
KD
DH
HL
LM
MO
OQ
QN
NP
PR
R
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.20 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 2 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 7 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 4 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 42 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Prevost, J. et al., Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir. Nat Commun (2023)
- Release Date
- 2023-07-19
- Peptides
- CRF-1_AE T/F100 Env gp120: AEI
CRF-1_AE T/F100 HIV-1 gp41: BFJ
Heavy chain of 8ANC195: CGK
Light chain of 8ANC195: DHL
Heavy chain of 10-1074: MOQ
Light chain of 10-1074: NPR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
EI
IB
BF
FJ
JC
CG
GK
KD
DH
HL
LM
MO
OQ
QN
NP
PR
R